Log in

NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Forecast & News

+0.39 (+0.66 %)
(As of 12/13/2019 08:06 AM ET)
Today's Range
Now: $59.14
50-Day Range
MA: $59.27
52-Week Range
Now: $59.14
Volume90,681 shs
Average Volume145,552 shs
Market Capitalization$808.44 million
P/E Ratio28.30
Dividend YieldN/A
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EGRX



Sales & Book Value

Annual Sales$213.31 million
Cash Flow$2.43 per share
Book Value$10.78 per share


Net Income$31.90 million


Market Cap$808.44 million
Next Earnings Date2/27/2020 (Estimated)

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) released its quarterly earnings data on Tuesday, November, 12th. The specialty pharmaceutical company reported $0.26 EPS for the quarter, missing analysts' consensus estimates of $0.43 by $0.17. The specialty pharmaceutical company had revenue of $41.10 million for the quarter, compared to the consensus estimate of $45.44 million. Eagle Pharmaceuticals had a return on equity of 16.07% and a net margin of 12.72%. Eagle Pharmaceuticals's revenue was down 19.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.18 earnings per share. View Eagle Pharmaceuticals' Earnings History.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Eagle Pharmaceuticals.

What price target have analysts set for EGRX?

3 Wall Street analysts have issued 1-year price targets for Eagle Pharmaceuticals' shares. Their forecasts range from $50.00 to $66.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $58.00 in the next twelve months. This suggests that the stock has a possible downside of 1.9%. View Analyst Price Targets for Eagle Pharmaceuticals.

What is the consensus analysts' recommendation for Eagle Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

What are Wall Street analysts saying about Eagle Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (10/17/2019)
  • 2. Cantor Fitzgerald analysts commented, ". Post 1Q19, we are reiterating our Neutral rating and our 12- month price target on EGRX shares of $58. Pipeline setbacks in 2018 have created an overhang on the visibility of near term growth drivers for EGRX, which keeps us on the sidelines for now. Given the current visibility, we believe EGRX stock remains fairly valued at current levels. That said, EGRX’s current business continues to perform well and the company is advancing Ryanodex for nerve agent exposure and acute radiation syndrome, both of which we believe have the potential to get into the strategic national stockpile, if successful." (5/7/2019)

Has Eagle Pharmaceuticals been receiving favorable news coverage?

News headlines about EGRX stock have been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eagle Pharmaceuticals earned a daily sentiment score of -1.7 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Eagle Pharmaceuticals.

Are investors shorting Eagle Pharmaceuticals?

Eagle Pharmaceuticals saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,470,000 shares, a decrease of 5.8% from the October 31st total of 1,560,000 shares. Based on an average daily trading volume, of 144,900 shares, the short-interest ratio is presently 10.1 days. Approximately 11.2% of the company's shares are sold short. View Eagle Pharmaceuticals' Current Options Chain.

Who are some of Eagle Pharmaceuticals' key competitors?

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Exelixis (EXEL), Gilead Sciences (GILD), Teekay Tankers (TNK), Celgene (CELG), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), Synergy Pharmaceuticals (SGYP), bluebird bio (BLUE), Radius Health (RDUS) and AbbVie (ABBV).

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the folowing people:
  • Mr. Scott L. Tarriff, CEO & Director (Age 59)
  • Mr. David M. Pernock, Pres & Chief Operating Officer (Age 66)
  • Mr. Pete A. Meyers, Chief Financial Officer (Age 49)
  • Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 58)
  • Mr. Daniel O'Connor, Exec. VP of Biologics & Corp. Devel. (Age 39)

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.96%), Chartwell Investment Partners LLC (1.37%), Smith Graham & Co. Investment Advisors LP (1.13%), Man Group plc (0.78%), Scout Investments Inc. (0.67%) and Foundry Partners LLC (0.56%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp, Sander A Flaum and Scott Tarriff. View Institutional Ownership Trends for Eagle Pharmaceuticals.

Which institutional investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Man Group plc, Squarepoint Ops LLC, Chartwell Investment Partners LLC, Pictet Asset Management Ltd., Scout Investments Inc., Systematic Financial Management LP and Convergence Investment Partners LLC. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View Insider Buying and Selling for Eagle Pharmaceuticals.

Which institutional investors are buying Eagle Pharmaceuticals stock?

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Chicago Equity Partners LLC, Millennium Management LLC, SG Americas Securities LLC, Public Employees Retirement System of Ohio, Alberta Investment Management Corp, California Public Employees Retirement System and Robeco Institutional Asset Management B.V.. View Insider Buying and Selling for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $59.14.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $808.44 million and generates $213.31 million in revenue each year. The specialty pharmaceutical company earns $31.90 million in net income (profit) each year or $2.09 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe.View Additional Information About Eagle Pharmaceuticals.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is http://www.eagleus.com/.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]

MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  380 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  636
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel